{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:36:36Z","timestamp":1791084996315,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Clonal hematopoiesis of indeterminate potential (CHIP) in patients with chronic lymphocytic leukemia (CLL) has not been extensively characterized. The objective of this study was to describe the prevalence of myeloid CHIP (M-CHIP) in patients with CLL, and to determine its association with time to first treatment (TTFT) and overall survival (OS). We retrospectively analyzed data from patients participating in a prospective CLL database at the Dana-Farber Cancer Institute who had standard-of-care targeted 95-gene next-generation sequencing (NGS) performed. A schema was devised to classify mutations as M-CHIP related. M-CHIP was analyzed as a binary (present\/absent) and categorical (\u22652 vs 1 vs 0 mutations) predictor. We included 966 patients (median age at time of NGS, 65 years; 38% female). Overall, 747 (77%) patients had NGS performed before CLL treatment, whereas 219\u00a0(23%) had it performed after receiving treatment. Median follow-up time from NGS was 1.9 years. The prevalence of M-CHIP in untreated (12%) and treated (24%) patients with CLL was similar to that described in previous literature. M-CHIP prevalence appeared to increase with age in untreated patients, but appeared consistent across age in treated patients, suggesting that treatment (85% had prior chemotherapy) may have an impact on M-CHIP emergence even in younger patients. The presence of \u22652 M-CHIP mutations was associated with OS, even accounting for prior treatment and age, but was driven by a small subset of patients (n\u00a0=\u00a028). M-CHIP was not associated with TTFT. These findings support continued work into characterizing the effects of M-CHIP in patients with CLL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013414","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:46:19Z","timestamp":1727300779000},"page":"5949-5956","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-1501","authenticated-orcid":false,"given":"Abi","family":"Vijenthira","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"2Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia O.","family":"Volpe","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin","family":"Sekar","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Santos Azevedo","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-2051","authenticated-orcid":false,"given":"Mariia","family":"Mikhaleva","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Gibson","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Martindale","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Fardoun","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-6507","authenticated-orcid":false,"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[{"name":"6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"7Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ren","sequence":"additional","affiliation":[{"name":"6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-9956","authenticated-orcid":false,"given":"Binyamin A.","family":"Knisbacher","sequence":"additional","affiliation":[{"name":"8The Mina and Everard Goodman Faculty of Life Sciences, Ramat Gan, Israel"},{"name":"9Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-7261","authenticated-orcid":false,"given":"Cynthia K.","family":"Hahn","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"9Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"9Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"10Department of Pathology, Massachusetts General Hospital, Boston, MA"},{"name":"11Krantz Family Center for Cancer Research and Dept. of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"9Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"5Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"11","key":"2024121014464779200_bib1","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","article-title":"Distinction of lymphoid and myeloid clonal hematopoiesis","volume":"27","author":"Niroula","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"2024121014464779200_bib2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","article-title":"Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis","volume":"32","author":"Arends","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2024121014464779200_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2018-01-829937","article-title":"Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A","volume":"132","author":"Buscarlet","year":"2018","journal-title":"Blood"},{"issue":"7709","key":"2024121014464779200_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"2","key":"2024121014464779200_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024121014464779200_bib6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024121014464779200_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjh.18129","article-title":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","volume":"198","author":"Voso","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"2024121014464779200_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J\u00a0Mol Diagn"},{"issue":"11","key":"2024121014464779200_bib9","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"key":"2024121014464779200_bib10","unstructured":"Genome Aggregation Database. gnomAD. 2022. Accessed 1 April 2022. https:\/\/gnomad.broadinstitute.org\/."},{"issue":"14","key":"2024121014464779200_bib11","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/bloodadvances.2024013228","article-title":"Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis","volume":"8","author":"Singh","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2024121014464779200_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024121014464779200_bib13","doi-asserted-by":"crossref","first-page":"EVIDoa2200310","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"20","key":"2024121014464779200_bib14","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease","volume":"81","author":"Gumuser","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"2024121014464779200_bib15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood.2022015384","article-title":"TET2-mutant clonal hematopoiesis and risk of gout","volume":"140","author":"Agrawal","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2024121014464779200_bib16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.2023022222","article-title":"Causes and consequences of clonal hematopoiesis","volume":"142","author":"Weeks","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2024121014464779200_bib17","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"18","key":"2024121014464779200_bib18","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024121014464779200_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024121014464779200_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7540","key":"2024121014464779200_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"2","key":"2024121014464779200_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024121014464779200_bib23","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024121014464779200_bib24","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/s41375-020-0795-z","article-title":"Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study","volume":"34","author":"Husby","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2024121014464779200_bib25","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.1002\/ajh.26558","article-title":"Cardiovascular disease in patients with chronic lymphocytic leukemia: a Swedish nationwide register study with matched comparators","volume":"97","author":"Larsson","year":"2022","journal-title":"Am J Hematol"},{"key":"2024121014464779200_bib26","unstructured":"Centers for Disease Control and Prevention. National Center for Health Statistics. Heart Disease Prevalence. 2024. Accessed 6 August 2024. https:\/\/www.cdc.gov\/nchs\/hus\/topics\/heart-disease-prevalence.htm."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5949\/2344933\/blooda_adv-2024-013414-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/5949\/2344933\/blooda_adv-2024-013414-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:47:35Z","timestamp":1733842055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/5949\/517993\/Myeloid-clonal-hematopoiesis-of-indeterminate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":26,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013414","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}